Search

ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).

Pride month at ProQR is an opportunity to celebrate and thank all of the LGBT+ people in our communities, including our employees, scientists, and doctors that made our research possible.

Throughout the year ProQR regularly welcomes student groups from across the Netherlands.

In this personal interview, we speak to ProQR’s Chief Corporate Development Officer & General Counsel, René Beukema on his return to ProQR.

In April 2025, ProQR received the Great Place To Work (GPTW) certification following the results of the employee survey from GPTW Netherlands.